Du sirolimus au stent Cypher®: lesétapes d'une victoire contre la restenose
Authors:
- I. FontesIFI. Fontes
- D. BarrowDBD. Barrow
- 31 May 2004
- journal article
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 53, S3-S8
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Rapamycin Reverses Chronic Graft Vascular Disease in a Novel Cardiac Allograft ModelCirculation, 1999
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- Rapamycin inhibits vascular smooth muscle cell migration.Journal of Clinical Investigation, 1996
- Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle CellsCirculation Research, 1995
- TREATMENT WITH RAPAMYCIN AND MYCOPHENOLIC ACID REDUCES ARTERIAL INTIMAL THICKENING PRODUCED BY MECHANICAL INJURY AND ALLOWS ENDOTHELIAL REPLACEMENTTransplantation, 1995
- Total synthesis of rapamycinJournal of the American Chemical Society, 1993
- RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG FOR VASCULARIZED HEART, KIDNEY, AND SMALL BOWEL TRANSPLANTATION IN THE RATTransplantation, 1991
- RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTINGThe Lancet, 1989
- Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action.The Journal of Antibiotics, 1979
- Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.The Journal of Antibiotics, 1975